X
BEAM icon

Xponance’s Beam Therapeutics BEAM Stock Holding History

Xponance’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$384K Buy
11,184
+2,115
+23% +$63.9K ﹤0.01% 1255
2026
Q1 		$216K Buy
9,069
+1,495
+20% +$41.5K ﹤0.01% 1436
2025
Q4 		$210K Buy
+7,574
New +$193K ﹤0.01% 1369
2021
Q4 		– Sell
-2,342
Closed -$204K – 1176
2021
Q3 		$204K Sell
2,342
-230
-9% -$23.1K ﹤0.01% 1116
2021
Q2 		$331K Buy
+2,572
New +$205K 0.01% 1050

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Xponance's BEAM Position: Q2 2026 in Review

Xponance increased its Beam Therapeutics (BEAM) stake by 23% in Q2 2026, buying an estimated $63.9K and bringing the position to 11,184 shares worth $384K. The position accounts for ﹤0.01% of the portfolio, ranked #1255.

Xponance first reported a position in BEAM in Q2 2021 and has held it in 5 quarters since. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Xponance held 11,184 shares of Beam Therapeutics worth $384K as of Q2 2026.
  • Xponance bought 2,115 Beam Therapeutics shares in Q2 2026, an estimated $63.9K.
  • Beam Therapeutics made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1255 holding.
  • Xponance first reported a position in Beam Therapeutics in Q2 2021 and has held it in 5 quarters since.
  • 278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.